

PRESS RELEASE

innate pharma

INNATE PHARMA ANNOUNCED ITS FINANCIAL AND INVESTOR RELATIONS CALENDAR FOR 2008

Marseilles, December 19, 2007


Innate Pharma (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, announced its tentative financial and investor relations calendar for 2008.

The tentative financial calendar was set as follows:

- February 6, 2008: Publication of revenue for 4Q2007 and for fiscal year 2007, with management comments
- March 14, 2008: Publication of 2007 financial statements, with management comments
Publication of the Reference Document 2007 and Financial Report (included in the Reference Document)
- May 5, 2008: Publication of revenue for 1Q2008, with management comments
- June 27, 2008: Annual shareholders meeting and analysts meeting, in Marseilles
- August 29, 2008: Publication of mid-year financial statements as of June 30, 2008, with management comments
- November 6, 2008: Publication of revenue for 3Q2008, with management comments
- February 6, 2009: Publication of revenue for 4Q2008 and for fiscal year 2008, with management comments

All corporate information on the company such as its financial statements or its corporate presentations is available on the company's website (www.innate-pharma.com), in the investor documentation centre, Investors' section.

As during 2007, Letters to Shareholders will be published on a regular basis throughout the year 2008.



PRESS RELEASE

innate pharma

About Innate Pharma

Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006, Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class* drugs targeting innate immunity.

The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings.

Besides cancer, Innate Pharma's drug candidates have development potential in the treatment of infectious disease and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials in cancer and viral infections.

With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing immunotherapeutics market.

Based in Marseilles, France, Innate Pharma had 82 employees as of September 30, 2007.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information:

ISIN code FR0010331421

Ticker code IPH

Disclaimer

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

For any additional information, please contact:

Innate Pharma

Laure-Hélène Mercier,
Director, Investor Relations
Phone: +33 (0)4 88 66 05 87
lmercier@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol
Phone: +33 (0)1 41 22 06 59
Mob: +33 (0)6 64 18 99 59
caroline@alizerp.com

* with new mechanisms of action.